Thomas Bogenrieder

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.

A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.

Journal: British journal of cancer

Published: January 25, 2023

CHK1 inhibition exacerbates replication stress induced by IGF blockade.

CHK1 inhibition exacerbates replication stress induced by IGF blockade.

Journal: Oncogene

Published: May 04, 2021

Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction.

Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction.

Journal: Cancer research

Published: August 23, 2020

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.

Journal: Breast cancer research : BCR

Published: July 03, 2020

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.

Journal: British journal of cancer

Published: June 06, 2019

Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models.

Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models.

Journal: Molecular cancer therapeutics

Published: May 07, 2019

Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis.

Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 06, 2018

Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer.

Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer.

Journal: Journal of cellular and molecular medicine

Published: February 22, 2018

Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor Stage.

Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor Stage.

Journal: Cancer research

Published: November 10, 2017

Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies.

Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies.

Journal: Targeted oncology

Published: August 18, 2017

Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer.

Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer.

Journal: Oncogene

Published: July 22, 2017

Non-reproducible sequence artifacts in FFPE tissue: an experience report.

Non-reproducible sequence artifacts in FFPE tissue: an experience report.

Journal: Journal of cancer research and clinical oncology

Published: February 25, 2017

Showing 1-12 of 15

Last Updated: 09/26/2026